Stryker Corporation logo
Stryker Corporation SYK
$ 276.43 0.68%
report update icon

Quarterly report 2026-Q2
added 07-31-2026

Stryker Corporation Cash Flow 2025-2006 | SYK

Brief overview of Stryker Corporation's cash movements

Cash flows are assessed across five available annual periods spanning 2021 to 2025.

Operating cash flow rose from $3.3 billion to $5 billion, or +54.6%, with CAGR near 11.5%. Cash generation expanded quickly.

Operating cash flow was positive in all five observations, adding repeatability to the cash profile.

Each unit of cumulative profit produced roughly 2.12x of operating cash flow. Earnings quality looks high.

At the end, 70.3% of revenue converted into operating cash flow versus 19.1% previously.

An additional $2.3 billion became tied up in estimated working capital, equal to 32.7% of revenue.

Overall picture

Stryker Corporation demonstrates high-quality cash generation. Operating and free cash flow leave a solid cushion for growth and obligations.

Annual Cash Flow Stryker Corporation

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006

Operating Cash Flow

5.04 B 4.24 B 3.71 B 2.62 B 3.26 B 3.28 B 2.19 B 2.61 B 1.56 B 1.92 B 981 M 1.78 B 1.89 B 1.66 B 1.43 B 1.55 B 1.46 B 1.18 B 1.03 B -

Depreciation & Amortization

1.57 B 1.43 B 1.34 B 1.28 B 1.27 B 1.08 B 1.04 B 966 M 859 M 752 M 590 M 586 M 511 M 486 M 481 M 410 M 385 M 155 M 137 M -

Accounts Payables

1.8 B 1.68 B 1.52 B 1.41 B 1.13 B 810 M 675 M 646 M 487 M 437 M 410 M 329 M 314 M 288 M 345 M 292 M 200 M 274 M - -

Accounts Receivables

4.04 B 3.99 B 3.76 B 3.56 B 3.02 B 2.7 B 2.89 B 2.33 B 2.2 B 1.97 B 1.66 B 1.57 B 1.52 B 1.43 B 1.42 B 1.25 B 1.15 B 1.13 B - -

Total Inventories

5.31 B 4.77 B 4.84 B 4 B 3.31 B 3.49 B 3.28 B 2.96 B 2.46 B 2.03 B 1.64 B 1.59 B 1.42 B 1.26 B 1.28 B 1.06 B 943 M 953 M - -

All numbers in USD currency

Quarterly Cash Flow Stryker Corporation

2026-Q2 2026-Q1 2025-Q3 2025-Q2 2025-Q1 2024-Q3 2024-Q2 2024-Q1 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1 2010-Q3 2010-Q2 2010-Q1 2009-Q3 2009-Q2

Operating Cash Flow

1.84 B 581 M - - 250 M - - 204 M - - 445 M - 1.62 B - 203 M - 2.26 B - 452 M - 2.04 B 1.21 B 591 M - 1.46 B 827 M 313 M - 1.56 B 946 M 297 M - 880 M 801 M 151 M - 1.26 B 755 M 262 M - 228 M 737 M 380 M - 535 M 366 M 209 M - 622 M 356 M 236 M - 569 M 457 M 35 M - 446 M 157 M 204 M 428 M 327 M 275 M 466 M 182 M

Depreciation & Amortization

404 M 397 M 404 M 389 M 361 M 371 M 354 M 355 M 164 M 161 M 96 M - 159 M 160 M 92 M - 278 M 149 M 95 M - 247 M 163 M 80 M - 231 M 153 M 76 M - 223 M 150 M 74 M - 198 M 127 M 62 M - 165 M 106 M 49 M - 137 M 90 M 45 M - 47 M 47 M 46 M - 42 M 43 M 38 M - 38 M 38 M 39 M - 40 M 39 M 40 M 39.7 M 39.1 M 40.8 M 41.1 M 38.9 M

Accounts Payables

1.66 B 1.59 B 1.5 B 1.44 B 1.46 B 1.34 B 1.3 B 1.25 B 1.3 B 1.33 B 1.37 B 1.41 B 1.21 B - 1.08 B 1.13 B 934 M 864 M 767 M 810 M 810 M 810 M 810 M 675 M 675 M 675 M 675 M 646 M 646 M 646 M 646 M 487 M 487 M 487 M 487 M 437 M 437 M 437 M 437 M 410 M 410 M 410 M 410 M 329 M 329 M 329 M 329 M 314 M 314 M 314 M 314 M 288 M 288 M 288 M 288 M 345 M 345 M 345 M 345 M 248 M 213 M 231 M 204 M 212 M

Accounts Receivables

3.74 B 3.57 B 3.64 B 3.92 B 3.96 B 3.74 B 3.62 B 3.47 B 3.28 B 3.26 B 3.22 B 3.56 B 3.1 B - 2.99 B 3.02 B 2.82 B 2.71 B 2.62 B 2.7 B 2.7 B 2.7 B 2.7 B 2.89 B 2.89 B 2.89 B 2.89 B 2.33 B 2.33 B 2.33 B 2.33 B 2.2 B 2.2 B 2.2 B 2.2 B 1.97 B 1.97 B 1.97 B 1.97 B 1.66 B 1.66 B 1.66 B 1.66 B 1.57 B 1.57 B 1.57 B 1.57 B 1.52 B 1.52 B 1.52 B 1.52 B 1.43 B 1.43 B 1.43 B 1.43 B 1.42 B 1.42 B 1.42 B 1.42 B 1.16 B 1.11 B 1.12 B 1.11 B 1.1 B

Total Inventories

5.52 B 5.42 B 5.37 B 5.29 B 5.1 B 5.29 B 5.04 B 5.03 B 4.88 B 4.59 B 4.33 B 4 B 3.88 B - 3.52 B 3.31 B 3.43 B 3.43 B 3.47 B 3.49 B 3.49 B 3.49 B 3.49 B 2.98 B 3.28 B 3.28 B 3.28 B 2.96 B 2.96 B 2.96 B 2.96 B 2.46 B 2.46 B 2.46 B 2.46 B 2.03 B 2.03 B 2.03 B 2.03 B 1.64 B 1.64 B 1.64 B 1.64 B 1.59 B 1.59 B 1.59 B 1.59 B 1.42 B 1.42 B 1.42 B 1.42 B 1.26 B 1.26 B 1.26 B 1.26 B 1.28 B 1.28 B 1.28 B 1.28 B 1.04 B 968 M 961 M 977 M 992 M

All numbers in USD currency

Cash Flow Statement is one of the three key financial reports of the company Stryker Corporation, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.

Main Sections of the Cash Flow Statement
  • Operating Activities
    This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash.
  • Investing Activities
    Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign.
  • Financing Activities
    Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.

The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.

Cash flow statements of other stocks in the Medical devices sector

Issuer Price % 24h Market Cap Country
Sintx Technologies Sintx Technologies
SINT
$ 1.74 6.75 % $ 4.83 M usaUSA
Smith & Nephew plc Smith & Nephew plc
SNN
$ 27.87 0.16 % $ 24.2 B britainBritain
Tandem Diabetes Care Tandem Diabetes Care
TNDM
$ 19.88 0.4 % $ 1.35 B usaUSA
Sensus Healthcare Sensus Healthcare
SRTS
$ 3.16 0.94 % $ 51.6 M usaUSA
Viemed Healthcare Viemed Healthcare
VMD
$ 8.79 0.78 % $ 342 M usaUSA
Varex Imaging Corporation Varex Imaging Corporation
VREX
$ 18.49 0.03 % $ 765 M usaUSA
NuVasive NuVasive
NUVA
- - $ 2.07 B usaUSA
Vivos Therapeutics Vivos Therapeutics
VVOS
$ 0.18 6.76 % $ 1.85 M usaUSA
TELA Bio TELA Bio
TELA
$ 0.83 1.05 % $ 39 M usaUSA
Beyond Air Beyond Air
XAIR
$ 3.38 0.93 % $ 28.1 B usaUSA
Zimmer Biomet Holdings Zimmer Biomet Holdings
ZBH
$ 94.22 0.69 % $ 18.7 B usaUSA
Cognyte Software Ltd. Cognyte Software Ltd.
CGNT
$ 8.23 0.71 % $ 600 M israelIsrael
Axonics Modulation Technologies Axonics Modulation Technologies
AXNX
- - $ 3.31 B usaUSA
BIOLASE BIOLASE
BIOL
- -13.19 % $ 166 K usaUSA
Conformis Conformis
CFMS
- - $ 16.4 M usaUSA
Cutera Cutera
CUTR
- -10.19 % $ 1.99 M usaUSA
Eargo Eargo
EAR
- - $ 10.2 M usaUSA
Medigus Ltd. Medigus Ltd.
MDGS
- 10.28 % $ 55.5 M israelIsrael
Inari Medical Inari Medical
NARI
- - $ 4.23 B usaUSA
Nemaura Medical Nemaura Medical
NMRD
- -17.8 % $ 2.74 M britainBritain
Neovasc Neovasc
NVCN
- - $ 111 M canadaCanada
SmileDirectClub SmileDirectClub
SDC
- -53.45 % $ 9.71 M usaUSA
Sientra Sientra
SIEN
- -16.59 % $ 10.3 M usaUSA
Silk Road Medical, Inc Silk Road Medical, Inc
SILK
- - $ 1.07 B usaUSA
Surgalign Holdings Surgalign Holdings
SRGA
- -32.98 % $ 1.68 M usaUSA
ShockWave Medical ShockWave Medical
SWAV
- - $ 12.3 B usaUSA
ThermoGenesis Holdings ThermoGenesis Holdings
THMO
- -25.84 % $ 171 K usaUSA
Talis Biomedical Corporation Talis Biomedical Corporation
TLIS
- 3.55 % $ 7.96 M usaUSA
Viveve Medical Viveve Medical
VIVE
- -15.35 % $ 1.71 M usaUSA
ViewRay ViewRay
VRAY
- 1.54 % $ 468 M usaUSA
Titan Medical Titan Medical
TMDI
- -26.32 % $ 19.6 M canadaCanada
Natus Medical Incorporated Natus Medical Incorporated
NTUS
- 1.94 % $ 1.05 B usaUSA
Acutus Medical Acutus Medical
AFIB
- -26.83 % $ 2.62 M usaUSA
Cardiovascular Systems Cardiovascular Systems
CSII
- 0.15 % $ 844 M usaUSA
Invacare Corporation Invacare Corporation
IVC
- - $ 24.7 M usaUSA
Profound Medical Corp. Profound Medical Corp.
PROF
$ 6.81 1.32 % $ 206 M canadaCanada
Tactile Systems Technology Tactile Systems Technology
TCMD
$ 21.73 0.09 % $ 497 M usaUSA
Abbott Laboratories Abbott Laboratories
ABT
$ 105.52 0.03 % $ 184 B usaUSA
Aethlon Medical Aethlon Medical
AEMD
$ 1.81 1.09 % $ 1.22 M usaUSA
AdaptHealth Corp. AdaptHealth Corp.
AHCO
$ 6.19 1.09 % $ 837 M usaUSA
Align Technology Align Technology
ALGN
$ 153.49 0.03 % $ 11.1 B usaUSA
Apyx Medical Corporation Apyx Medical Corporation
APYX
$ 3.05 0.33 % $ 125 M usaUSA
Accuray Incorporated Accuray Incorporated
ARAY
$ 0.26 0.37 % $ 31.9 M usaUSA
Alphatec Holdings Alphatec Holdings
ATEC
$ 9.19 1.29 % $ 1.38 B usaUSA
AxoGen AxoGen
AXGN
$ 46.69 2.51 % $ 2.15 B usaUSA
Butterfly Network Butterfly Network
BFLY
$ 7.52 2.17 % $ 1.86 B usaUSA